Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Phase 3Recruiting
- Lead sponsor
- IDEAYA Biosciences (Industry)
- Enrollment
- 520 (estimated)
- Start date
- 25 Jan 2026
- Primary completion
- Oct 2030 (estimated)
- Study completion
- 1 Mar 2031
- Last update posted
- 6 May 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Darovasertib Drug
- Primary Local Therapy Procedure
Conditions and primary outcome
- Uveal Melanoma
Primary outcome
Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm (Approximately 3 years); Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm (Approximately 2 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07015190.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07015190 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.